AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma

• Published in: Journal of clinical oncology Vol. 42; no. 3_suppl; p. TPS720
• Main Authors: Chung, Vincent, Devoe, Craig E., George, Thomas J., Welkowsky, Esther, Kheoh, Thian, Haqq, Christopher M., Pant, Shubham, O'Reilly, Eileen Mary
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 20.01.2024

TPS720Background: KRAS mutations occur in 25% of human tumors, frequently in pancreatic where over 85% relapse after locoregional treatment. ELI-002 7P is a lymph node targeted immunotherapy comprised of Amphiphile (Amph)-modified G12D, G12R, G12V, G12C, G12A, G12S and G13D mutant KRAS peptides toge...